The phototherapy equipment market is projected to reach USD 0.62 billion by 2031, up from USD 0.47 billion in 2026, at a CAGR of 5.5%.
Continuous technological innovation, particularly the transition from conventional fluorescent and halogen light sources to LED-based phototherapy systems, is significantly driving market growth. LED phototherapy devices offer multiple advantages, including higher energy efficiency, longer operational lifespan, reduced heat emission, and precise wavelength targeting, which enhances treatment effectiveness while minimizing risks. These systems also provide uniform light distribution, improving clinical outcomes in both neonatal and dermatological applications.
Additionally, advancements in device design have led to the development of compact, user-friendly, and low-maintenance systems, making them more accessible to healthcare facilities with varying resource levels. Manufacturers are also integrating smart features such as digital displays, intensity controls, and automated timers, which improve usability and treatment accuracy. The growing preference for technologically advanced solutions among healthcare providers is accelerating the replacement of older equipment with modern LED-based systems. This ongoing innovation cycle not only improves patient outcomes but also creates a steady global demand for upgraded phototherapy equipment.
Additionally, the availability of well-equipped neonatal intensive care units ensures that even high-risk infants receive immediate treatment. This infrastructure not only facilitates access to phototherapy but also encourages healthcare providers to invest in technologically advanced systems such as LED-based devices. Furthermore, regular upgrades and maintenance of medical equipment, driven by stringent quality standards, contribute to sustained demand. The presence of such a robust healthcare ecosystem ensures consistent utilization and adoption of phototherapy devices across multiple care settings.
Continuous technological innovation, particularly the transition from conventional fluorescent and halogen light sources to LED-based phototherapy systems, is significantly driving market growth. LED phototherapy devices offer multiple advantages, including higher energy efficiency, longer operational lifespan, reduced heat emission, and precise wavelength targeting, which enhances treatment effectiveness while minimizing risks. These systems also provide uniform light distribution, improving clinical outcomes in both neonatal and dermatological applications.
Additionally, advancements in device design have led to the development of compact, user-friendly, and low-maintenance systems, making them more accessible to healthcare facilities with varying resource levels. Manufacturers are also integrating smart features such as digital displays, intensity controls, and automated timers, which improve usability and treatment accuracy. The growing preference for technologically advanced solutions among healthcare providers is accelerating the replacement of older equipment with modern LED-based systems. This ongoing innovation cycle not only improves patient outcomes but also creates a steady global demand for upgraded phototherapy equipment.
- Based on product: One of the most significant drivers of the dominance of conventional phototherapy equipment is its cost advantage over advanced alternatives, such as LED-based and fiber-optic systems. Conventional units typically have lower upfront acquisition costs, making them highly attractive for hospitals operating under tight budget constraints. In addition to capital expenditure, these systems also incur lower maintenance and servicing costs due to their simpler design and readily available components. This affordability becomes particularly crucial in price-sensitive markets, where healthcare providers must balance quality care with financial limitations. Public hospitals, small clinics, and rural healthcare centers often prioritize cost-effective solutions that can deliver acceptable clinical outcomes without significant investment. Moreover, large-scale procurement programs, especially in government-funded healthcare systems, tend to favor conventional equipment due to its economic viability. This strong cost-benefit equation ensures that conventional phototherapy remains widely accessible and continues to dominate market demand despite the availability of technologically advanced alternatives.
- Based on application: Phototherapy is universally recognized as the first-line treatment for neonatal hyperbilirubinemia due to its proven safety, efficacy, and non-invasive nature. It works by converting bilirubin into water-soluble isomers that can be excreted without requiring liver conjugation. Clinical guidelines across major health organizations strongly recommend phototherapy as the initial intervention before considering more invasive procedures such as exchange transfusion. This strong clinical endorsement ensures that phototherapy devices are routinely used in hospitals, particularly in NICUs and maternity centers. The treatment is easy to administer, requires minimal training, and has a low risk of adverse effects, making it suitable for widespread use even in resource-limited settings. Additionally, advancements such as LED-based phototherapy systems have further improved treatment efficiency and reduced operational costs, reinforcing its position as the preferred treatment modality. As a result, healthcare providers consistently rely on phototherapy equipment, which drives its dominant share in the neonatal jaundice segment.
Additionally, the availability of well-equipped neonatal intensive care units ensures that even high-risk infants receive immediate treatment. This infrastructure not only facilitates access to phototherapy but also encourages healthcare providers to invest in technologically advanced systems such as LED-based devices. Furthermore, regular upgrades and maintenance of medical equipment, driven by stringent quality standards, contribute to sustained demand. The presence of such a robust healthcare ecosystem ensures consistent utilization and adoption of phototherapy devices across multiple care settings.
A breakdown of the primary participants (supply-side) for the phototherapy equipment market referred to in this report is provided below:
- By Company Type: Tier 1:34%, Tier 2: 38%, and Tier 3: 28%
- By Designation: C-level: 26%, Director Level: 35%, and Others: 39%
- By Region: North America: 17%, Europe: 39%, Asia Pacific: 28%, Latin America: 8%, Middle East & Africa: 3%, GCC Countries: 5%
Research Coverage
The report evaluates the phototherapy equipment market and estimates the market size and future growth potential of this market based on various segments, including product, application, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.Reasons to Buy the Report
The report will assist the market leader and new entrants with data on the nearest approximations of revenue for the overall market, the phototherapy equipment market, and its subsegments. The report will assist stakeholders in understanding the competitive landscape and in gaining further insights to better position their businesses and develop appropriate go-to-market strategies. The report assists the stakeholders in understanding the market pulse and gives them data on influential drivers, hindrances, obstacles, and opportunities in the market.This report provides insights into the following points:
- Analysis of key drivers (rising incidence of neonatal jaundice, rising number of preterm and low-weight births, rising prevalence of skin diseases, launch of technologically advanced phototherapy equipment, rising adoption of LED-based phototherapy equipment), restraints (high use of alternative modes of treatment, stringent FDA regulatory policies for the approval of new devices), opportunities (development of low-cost phototherapy equipment, rising adoption of home phototherapy for the treatment of skin diseases), and challenges (rising trend of purchasing refurbished phototherapy equipment in emerging markets, limited adoption of phototherapy equipment in developing nations)
- Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global phototherapy equipment market
- Market Development: Thorough knowledge and analysis of the profitable rising markets by product, application, end user, and region.
- Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global phototherapy equipment market
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global phototherapy equipment market
Table of Contents
1 Introduction
2 Executive Summary
3 Premium Insights
4 Market Overview
5 Industry Trends
6 Technological Advancements, AI-Driven Impact, Patents, Innovations, and Future Applications
7 Customer Landscape & Buyer Behavior
8 Regulatory Landscape
9 Phototherapy Equipment Market, by Product
10 Phototherapy Equipment Market, by Application
11 Phototherapy Equipment Market, by End User
12 Phototherapy Equipment Market, by Region
13 Competitive Landscape
14 Company Profiles
15 Research Methodology
16 Appendix
List of Tables
List of Figures
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Merck Kgaa
- Danaher Corporation
- Shimadzu Corporation
- Waters Corporation
- Bio-Rad Laboratories, Inc.
- Bruker
- Revvity
- Illumina, Inc.
- Promega Corporation
- Eurofins Scientific
- Qiagen
- Charles River Laboratories
- Protagene
- Bio-Techne
- Azenta US Inc.
- Quanterix
- Proteomics International
- Hamilton Company
- Creative Proteomics
- Horiba, Ltd.
- Labvantage-Biomax GmbH
- Fios Genomics
- Medgenome
- Biognosys AG
- Macrogen, Inc.
- Cell Signaling Technology, Inc.
- Standard Biotools
- Pixelgen Technologies
- Applied Biomics
- Quantum-Si Incorporated
- Erisyon Inc.
- Nautilus Biotechnology, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 229 |
| Published | May 2026 |
| Forecast Period | 2026 - 2031 |
| Estimated Market Value ( USD | $ 0.47 Billion |
| Forecasted Market Value ( USD | $ 0.62 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 34 |
